Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Johnson, M.R.
Right arrow Articles by Steer, P.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, M.R.
Right arrow Articles by Steer, P.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. 5, pp. 1105-1108, 1996
© 1996 European Society of Human Reproduction and Embryology

research-article

The role of relaxin in the pregnancy associated reduction in plasma osmolality

M.R. Johnson1, A.A. Brooks and P.J. Steer

Academic Department of Obstetrics and Gynaecology, Charing Cross and Westminster Medical School, The Chelsea and Westminster Hospital 369 Fulham Road, London SW10 9NH, UK

Correspondence: 1To whom correspondence should be addressed

Recent data suggest that the ovarian peptide relaxin is responsible for the pregnancy-associated fall in plasma osmolality in the rat. In order to test whether relaxin has the same role during human pregnancy, plasma osmolality, electrolytes, urea and creatinine were measured in samples obtained at 10, 20 and 30 weeks gestation from singleton pregnancies conceived following ovum donation (OD, n = 12), spontaneously (N, n = 12) and following in-vitro fertilization and embryo transfer (IVF, n = 14). These groups were chosen, as relaxin concentrations throughout pregnancy are undetectable (OD), elevated (IVF) or normal (N). Thus, if relaxin alone is responsible for the fall in plasma osmolality associated with pregnancy in the human, then plasma osmolality would be expected not to fall during pregnancy in the OD group and to show a consistent decline from OD to N to IVF throughout pregnancy. Plasma osmolality fell significantly during pregnancy in both the OD and N groups, but not the IVF group. In addition, plasma osmolality was only significantly greater in OD when compared with IVF group at 10 weeks gestation; thereafter there were no significant differences between the groups with regard to plasma osmolality. Similarly, at 10 weeks the plasma concentrations of sodium and potassium were significantly higher in the OD than in either the N or IVF groups. Thus, although relaxin may be important in the initial control of plasma osmolality, other factors, probably derived from or regulated by the feto-placental unit, supersede it as pregnancy advances.

Key words: IVF/ovum donation/plasma osmolality/pregnancy/relaxin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. C. Smith, Lee. A. Danielson, Kirk. P. Conrad, and J. M. Davison
Influence of Recombinant Human Relaxin on Renal Hemodynamics in Healthy Volunteers
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3192 - 3197.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. A. Bathgate, R. Ivell, B. M. Sanborn, O. D. Sherwood, and R. J. Summers
International Union of Pharmacology LVII: Recommendations for the Nomenclature of Receptors for Relaxin Family Peptides.
Pharmacol. Rev., March 1, 2006; 58(1): 7 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
T. Hines, J. Veeh, and D. Grimes
The hypo-osmolality of pregnancy does not alter baroreceptor responses to acute changes in osmolality.
Biol Res Nurs, January 1, 2006; 7(3): 214 - 221.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
O. D. Sherwood
Relaxin's Physiological Roles and Other Diverse Actions
Endocr. Rev., April 1, 2004; 25(2): 205 - 234.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.